logo-loader
viewPropanc Biopharma, Inc.

Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal

The study confirmed the effects its drug against cancer stem cells within tumors that are capable of self-renewal and often resist chemotherapy

Cancer stem cell
PRP is a formulation of two pancreatic proenzymes, which work together to fight malignant tumors

Propanc Biopharma Inc (OTCMKTS:PPCBD), a biopharmaceutical company focused on using pancreatic proenzymes to treat recurring and metastatic cancer, said it has published key data regarding its lead drug PRP in the medical journal Scientific Reports.

In a statement, the company said it’s researchers, in collaboration with the Universities of Jaén and Granada in Spain, conducted a study that confirmed the effects of PRP against cancer stem cells, a select group of cells within tumors that are capable of self-renewal and often resist chemotherapy.

PRP is a formulation of two pancreatic proenzymes, which work together to fight malignant tumors. The results of the study come as Propanc is preparing for a First-in-Human trial of the drug in 2020.

READ: Propanc Biopharma moves closer to first-in-human study by quantifying ingredients for its metastatic cancer drug

“We are excited to publish this paper on our work with PRP and CSCs, where these cells drive cancer,” Propanc's Chief Science Officer Julian Kenyon said in the statement. 

“PRP has multiple modes of action, quite unlike any other cancer drug and is clearly in a class of its own. This is likely to translate into PRP being effective in many different cancer types and reducing the recurrence rate after standard treatments.”

The Scientific Reports article is entitled “Pancreatic proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumor engrafting”

Propanc's share price slid 9.6% to $1.99 on Monday.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Propanc Biopharma, Inc.

Price: 0.21 USD

OTCQB:PPCB
Market: OTCQB
Market Cap: $275.42 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bioscience and Cannadips CEO’s discuss key point of...

Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka and Case Mandel, CEO of Cannadips joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California. Bunka telling Proactive...

16 hours, 8 minutes ago

2 min read